Invicro

📖 Wiki Page

organization554 wordssynced 2026-04-02

Invicro

Type: Contract Research Organization (CRO) Location: Boston, MA, USA (with global operations) Founded: 2009 (spun out from Harvard Medical School imaging research) Website: [invicro.com](https://www.invicro.com/) Formerly: inviCRO (branding updated)

Overview

flowchart TD organizations_invicro["Invicro"] style organizations_invicro fill:#4fc3f7,stroke:#333,color:#000 organizations_invicr_0["Services and Expertise"] organizations_invicro -->|"includes"| organizations_invicr_0 style organizations_invicr_0 fill:#81c784,stroke:#333,color:#000 organizations_invicr_1["Imaging Core Laboratory Services"] organizations_invicro -->|"includes"| organizations_invicr_1 style organizations_invicr_1 fill:#ef5350,stroke:#333,color:#000 organizations_invicr_2["Neuroscience Focus Areas"] organizations_invicro -->|"includes"| organizations_invicr_2 style organizations_invicr_2 fill:#ffd54f,stroke:#333,color:#000 organizations_invicr_3["Quantification Platforms"] organizations_invicro -->|"includes"| organizations_invicr_3 style organizations_invicr_3 fill:#ce93d8,stroke:#333,color:#000 organizations_invicr_4["Role in PSP Clinical Trials"] organizations_invicro -->|"includes"| organizations_invicr_4 style organizations_invicr_4 fill:#4fc3f7,stroke:#333,color:#000 organizations_invicr_5["4R Tau Ligand Development NCT07348276"] organizations_invicro -->|"includes"| organizations_invicr_5 style organizations_invicr_5 fill:#81c784,stroke:#333,color:#000

...

Invicro

Overview

Mermaid diagram (expand to render)

Invicro is a specialty contract research organization (CRO) providing imaging core laboratory services, quantitative image analysis, and scientific consulting for clinical trials. Founded by researchers from Harvard Medical School's Center for Morphometric Analysis, Invicro has become a leading provider of neuroimaging core lab services for neurodegeneration trials, including multiple 4R tau PET imaging programs for PSP["@invicro2024"].

Invicro operates as a central imaging core for pharmaceutical companies and academic consortia, providing standardized image acquisition protocols, quality control, and centralized analysis across international multi-site trials. Their expertise in tau PET quantification has made them a key partner in PSP therapeutic development programs.

Services and Expertise

Imaging Core Laboratory Services

PET/MRI acquisition protocols: Standardized imaging protocols for multi-site trials
Quality control: Centralized image quality review and artifact detection
Tracer-specific quantification: Expertise in tau PET ligand analysis (flortaucipir, PI-2620, novel 4R tracers)
Longitudinal analysis: Tracking imaging biomarkers over time in clinical trials

Neuroscience Focus Areas

Invicro specializes in neuroimaging for:

Tauopathies: Alzheimer's disease, PSP, CBD, and other tauopathies
Alpha-synucleinopathies: Parkinson's disease, MSA, DLB
Neuroinflammation: TSPO PET for microglial activation
Neurodegeneration biomarkers: Volume loss, connectivity changes, network瓦解

Quantification Platforms

Syngo.via: Siemens-based quantification platform
PMOD: Medical imaging analysis suite
Capiris: Automated brain segmentation and region-of-interest tools
Custom pipelines: Client-specific analysis workflows

Role in PSP Clinical Trials

4R Tau Ligand Development (NCT07348276)

Invicro serves as the imaging core for the first-in-human study of novel 4R tau-selective PET radioligands (ABBV-964i and ABBV-965i) in PSP patients[@trial2024]. Their role includes:

Developing and validating standardized acquisition protocols for novel tracers
Cross-site harmonization of PET quantification
Central reading of imaging endpoints
Kinetic modeling analysis for new 4R-specific ligands

Tau PET Standardization for PSP

Invicro has contributed to standardization efforts for tau PET imaging in PSP:

Participating in multi-center phantom studies for PET scanner calibration
Developing region-of-interest templates specific to PSP subcortical structures
Establishing reference regions for specific binding quantification
Supporting regulatory submissions with imaging data packages

PROSPER Trial Support

While Ferrer leads the PROSPER Phase 2 trial of FNP-223 in PSP (NCT06355531), Invicro has provided imaging consultation for related tau biomarker studies, contributing to the development of OGA inhibitor imaging endpoints[@ferrer2025].

Key PSP Trial Partnerships

| Trial | Sponsor | Role |
|-------|---------|------|
| First-in-Human 4R Tau Ligand (NCT07348276) | Invicro (as sponsor) | Full imaging core lab |
| PI-2620 Tau PET (NCT04715750) | Life Molecular Imaging | Quantitative analysis |
| Biomarkers in Parkinsonian Syndromes (NCT06501469) | Academic consortium | Imaging consultation |

Corporate Structure

Invicro operates under the [IXICO Technologies](/companies/ixico-technologies) umbrella following acquisition, combining IXICO's digital biomarker expertise with Invicro's imaging core capabilities[@ixico2023]. This integration provides:

End-to-end imaging and digital biomarker services
Combined regulatory expertise across US and EU
Expanded site network for international trials

Cross-References

[Life Molecular Imaging](/companies/life-molecular-imaging) — Partner for PI-2620 PET tracer
[Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy) — Primary disease focus
[4R-Tauopathies](/mechanisms/4r-tauopathies) — Mechanism under study
[Tau PET Imaging](/mechanisms/tau-pathology#tau-pet-imaging) — Imaging modality
[IXICO Technologies](/companies/ixico-technologies) — Parent company

External Links

[Invicro Official Website](https://www.invicro.com/)
[Invicro Neuroscience Services](https://www.invicro.com/services/neuroscience/)
[Clinical Trials using Invicro Imaging Core](https://clinicaltrials.gov/)

Pathway Diagram

The following diagram shows the key molecular relationships involving Invicro discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →